![](https://ml-eu.globenewswire.com/media/84159208-c519-49a5-86c6-56151e3ab92b/small/ena-png.png)
ENA Respiratory Progresses Phase Ib Study of its Dry Powder Formulation of Intranasal Innate Immunomodulator INNA-051
Advances a new formulation with improved stability in the clinic Single ascending dose phase successfully completed, multiple ascending dose phase underway MELBOURNE, Australia, Aug. 27, 2024 (GLOBE NEWSWIRE) -- ENA Respiratory, a clinical-stage …